Design and implementation of a novel pharmacogenetic assay for the identification of the CYP2D6*10 genetic variant.

Publisher: Biomed Central Country of Publication: England NLM ID: 101462768 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-0500 (Electronic) Linking ISSN: 17560500 NLM ISO Abbreviation: BMC Res Notes Subsets: MEDLINE

Original Publication: London : Biomed Central, 2008.

Cytochrome P-450 CYP2D6*/genetics ; Cytochrome P-450 CYP2D6*/metabolism ; Pharmacogenetics*; Antineoplastic Agents, Hormonal/metabolism ; Female ; Genotype ; Humans ; Tamoxifen/therapeutic use

Objectives: Tamoxifen is considered to be the most widely used adjuvant therapy for hormone receptor positive breast cancer in premenopausal women. However, it is reported that nearly 30% of patients receiving tamoxifen therapy have shown reduced or no benefits. This may be due to the high inter-individual variations in the CYP2D6 gene that is involved in tamoxifen metabolism. The CYP2D6*10 gene variant (rs1065852C>T) is reported to be commonly found in Asian and South Asian populations. The present study was undertaken to design a novel pharmacogenetic assay (Single step-Tetra Arms Polymerase Chain Reaction) for the identification of the CYP2D6*10 variant and implement the designed assay by genotyping a cohort of breast cancer patients.
Results: The novel assay was successfully designed, optimized and validated using Sanger sequencing. Blood samples from 70 patients were genotyped. The following bands were observed in the gel image: Control band at 454 bp; band for C allele at 195 bp; band for T allele at 300 bp. The genotype frequencies for the CYP2D6*10 (rs1065852C>T) variant were: CC-24.28% (17/70), CT-75.71% (53/70), TT-0% (0/70). The allele frequencies were: T-allele-37.86% and C-allele-62.14%.
(© 2022. The Author(s).)

BMC Res Notes. 2018 Feb 15;11(1):132. (PMID: 29448951)
J Clin Lab Anal. 2020 Jan;34(1):e23005. (PMID: 31441095)
Mol Biotechnol. 2014 Jul;56(7):599-608. (PMID: 24519268)
Biomed Rep. 2018 Nov;9(5):446-452. (PMID: 30345040)
Pharmacogenet Genomics. 2009 Jul;19(7):559-62. (PMID: 19512959)
Pharmaceuticals (Basel). 2010 Apr 15;3(4):1122-1138. (PMID: 27713292)
Methods Protoc. 2019 Jul 25;2(3):. (PMID: 31349745)
Indian J Hum Genet. 2013 Oct;19(4):392-6. (PMID: 24497701)
Int J Cancer. 2019 Apr 15;144(8):1941-1953. (PMID: 30350310)

Keywords: Breast cancer; CYP2D6*10; Genotypes; Pharmacogenetics; Tamoxifen

0 (Antineoplastic Agents, Hormonal)
094ZI81Y45 (Tamoxifen)
EC 1.14.14.1 (Cytochrome P-450 CYP2D6)

Date Created: 20220317 Date Completed: 20220318 Latest Revision: 20220324

20240829

PMC8925205

10.1186/s13104-022-05993-6

35296326